Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G 0-G1 cell cycle arrest

Matthew C. Ralstin, Earl A. Gage, Michele T. Yip-Schneider, Patrick J. Klein, Eric A. Wiebke, C. Max Schmidt

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Chemotherapy to date has not been effective in the treatment of human hepatocellular carcinoma. More effective treatment strategies may involve combinations of agents with activity against hepatocellular carcinoma. Parthenolide, a nuclear factor-κB (NF-κB) inhibitor, and NS398, a cyclooxygenase (COX)-2 inhibitor, have been shown to individually suppress the growth of hepatocellular carcinoma cells in vitro. To investigate their effects in combination, three human hepatocellular carcinoma lines (Hep3B, HepG2, and PLC) were treated with parthenolide and/or NS398. Parthenolide (0.1-10 μmol/L) and NS398 (1-100 μmol/L) each caused concentration-dependent growth inhibition in all cell lines. The addition of parthenolide to NS398 reduced the concentration of NS398 required to inhibit hepatocellular carcinoma growth. Because parthenolide and COX-2 inhibitors have been reported to influence NF-κB activity, the effects on this pathway were investigated. The combination of parthenolide/NS398 inhibited phosphorylation of the NF-κB-inhibitory protein IκBα and increased total IκBα levels. NF-κB DNA-binding and transcriptional activities were inhibited more by the combination than the single agents in Hep3B and HepG2 cells but not in PLC cells. The response of PLC cells to NS398 was augmented by p65 small interfering RNA to inhibit NF-κB p65 protein expression. The combination of parthenolide/NS398 increased apoptosis only in PLC cells, suggesting that the combination may decrease the apoptotic threshold in these cells. In Hep3B and HepG2 cells, combination treatment with NS398/parthenolide altered the cell cycle distribution resulting in more G0-G 1 accumulation. Cyclin D1 levels were further decreased by combination treatment in all cell lines, correlating with the cell cycle alterations. Our results suggest that parthenolide may be effective in combination with COX-2 inhibitors for the treatment of hepatocellular carcinoma.

Original languageEnglish (US)
Pages (from-to)387-399
Number of pages13
JournalMolecular Cancer Research
Volume4
Issue number6
DOIs
StatePublished - Jun 1 2006

Fingerprint

G1 Phase Cell Cycle Checkpoints
Hepatocellular Carcinoma
Apoptosis
Growth
Cyclooxygenase 2 Inhibitors
Hep G2 Cells
Cell Cycle
parthenolide
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
Cell Line
Cyclin D1
Small Interfering RNA
Proteins
Therapeutics
Phosphorylation
Drug Therapy

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G 0-G1 cell cycle arrest. / Ralstin, Matthew C.; Gage, Earl A.; Yip-Schneider, Michele T.; Klein, Patrick J.; Wiebke, Eric A.; Schmidt, C. Max.

In: Molecular Cancer Research, Vol. 4, No. 6, 01.06.2006, p. 387-399.

Research output: Contribution to journalArticle

@article{e90dc7663f9343a0874b8f0ddcb9aa98,
title = "Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G 0-G1 cell cycle arrest",
abstract = "Chemotherapy to date has not been effective in the treatment of human hepatocellular carcinoma. More effective treatment strategies may involve combinations of agents with activity against hepatocellular carcinoma. Parthenolide, a nuclear factor-κB (NF-κB) inhibitor, and NS398, a cyclooxygenase (COX)-2 inhibitor, have been shown to individually suppress the growth of hepatocellular carcinoma cells in vitro. To investigate their effects in combination, three human hepatocellular carcinoma lines (Hep3B, HepG2, and PLC) were treated with parthenolide and/or NS398. Parthenolide (0.1-10 μmol/L) and NS398 (1-100 μmol/L) each caused concentration-dependent growth inhibition in all cell lines. The addition of parthenolide to NS398 reduced the concentration of NS398 required to inhibit hepatocellular carcinoma growth. Because parthenolide and COX-2 inhibitors have been reported to influence NF-κB activity, the effects on this pathway were investigated. The combination of parthenolide/NS398 inhibited phosphorylation of the NF-κB-inhibitory protein IκBα and increased total IκBα levels. NF-κB DNA-binding and transcriptional activities were inhibited more by the combination than the single agents in Hep3B and HepG2 cells but not in PLC cells. The response of PLC cells to NS398 was augmented by p65 small interfering RNA to inhibit NF-κB p65 protein expression. The combination of parthenolide/NS398 increased apoptosis only in PLC cells, suggesting that the combination may decrease the apoptotic threshold in these cells. In Hep3B and HepG2 cells, combination treatment with NS398/parthenolide altered the cell cycle distribution resulting in more G0-G 1 accumulation. Cyclin D1 levels were further decreased by combination treatment in all cell lines, correlating with the cell cycle alterations. Our results suggest that parthenolide may be effective in combination with COX-2 inhibitors for the treatment of hepatocellular carcinoma.",
author = "Ralstin, {Matthew C.} and Gage, {Earl A.} and Yip-Schneider, {Michele T.} and Klein, {Patrick J.} and Wiebke, {Eric A.} and Schmidt, {C. Max}",
year = "2006",
month = "6",
day = "1",
doi = "10.1158/1541-7786.MCR-05-0157",
language = "English (US)",
volume = "4",
pages = "387--399",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G 0-G1 cell cycle arrest

AU - Ralstin, Matthew C.

AU - Gage, Earl A.

AU - Yip-Schneider, Michele T.

AU - Klein, Patrick J.

AU - Wiebke, Eric A.

AU - Schmidt, C. Max

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Chemotherapy to date has not been effective in the treatment of human hepatocellular carcinoma. More effective treatment strategies may involve combinations of agents with activity against hepatocellular carcinoma. Parthenolide, a nuclear factor-κB (NF-κB) inhibitor, and NS398, a cyclooxygenase (COX)-2 inhibitor, have been shown to individually suppress the growth of hepatocellular carcinoma cells in vitro. To investigate their effects in combination, three human hepatocellular carcinoma lines (Hep3B, HepG2, and PLC) were treated with parthenolide and/or NS398. Parthenolide (0.1-10 μmol/L) and NS398 (1-100 μmol/L) each caused concentration-dependent growth inhibition in all cell lines. The addition of parthenolide to NS398 reduced the concentration of NS398 required to inhibit hepatocellular carcinoma growth. Because parthenolide and COX-2 inhibitors have been reported to influence NF-κB activity, the effects on this pathway were investigated. The combination of parthenolide/NS398 inhibited phosphorylation of the NF-κB-inhibitory protein IκBα and increased total IκBα levels. NF-κB DNA-binding and transcriptional activities were inhibited more by the combination than the single agents in Hep3B and HepG2 cells but not in PLC cells. The response of PLC cells to NS398 was augmented by p65 small interfering RNA to inhibit NF-κB p65 protein expression. The combination of parthenolide/NS398 increased apoptosis only in PLC cells, suggesting that the combination may decrease the apoptotic threshold in these cells. In Hep3B and HepG2 cells, combination treatment with NS398/parthenolide altered the cell cycle distribution resulting in more G0-G 1 accumulation. Cyclin D1 levels were further decreased by combination treatment in all cell lines, correlating with the cell cycle alterations. Our results suggest that parthenolide may be effective in combination with COX-2 inhibitors for the treatment of hepatocellular carcinoma.

AB - Chemotherapy to date has not been effective in the treatment of human hepatocellular carcinoma. More effective treatment strategies may involve combinations of agents with activity against hepatocellular carcinoma. Parthenolide, a nuclear factor-κB (NF-κB) inhibitor, and NS398, a cyclooxygenase (COX)-2 inhibitor, have been shown to individually suppress the growth of hepatocellular carcinoma cells in vitro. To investigate their effects in combination, three human hepatocellular carcinoma lines (Hep3B, HepG2, and PLC) were treated with parthenolide and/or NS398. Parthenolide (0.1-10 μmol/L) and NS398 (1-100 μmol/L) each caused concentration-dependent growth inhibition in all cell lines. The addition of parthenolide to NS398 reduced the concentration of NS398 required to inhibit hepatocellular carcinoma growth. Because parthenolide and COX-2 inhibitors have been reported to influence NF-κB activity, the effects on this pathway were investigated. The combination of parthenolide/NS398 inhibited phosphorylation of the NF-κB-inhibitory protein IκBα and increased total IκBα levels. NF-κB DNA-binding and transcriptional activities were inhibited more by the combination than the single agents in Hep3B and HepG2 cells but not in PLC cells. The response of PLC cells to NS398 was augmented by p65 small interfering RNA to inhibit NF-κB p65 protein expression. The combination of parthenolide/NS398 increased apoptosis only in PLC cells, suggesting that the combination may decrease the apoptotic threshold in these cells. In Hep3B and HepG2 cells, combination treatment with NS398/parthenolide altered the cell cycle distribution resulting in more G0-G 1 accumulation. Cyclin D1 levels were further decreased by combination treatment in all cell lines, correlating with the cell cycle alterations. Our results suggest that parthenolide may be effective in combination with COX-2 inhibitors for the treatment of hepatocellular carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=33745870112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745870112&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-05-0157

DO - 10.1158/1541-7786.MCR-05-0157

M3 - Article

C2 - 16778086

AN - SCOPUS:33745870112

VL - 4

SP - 387

EP - 399

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 6

ER -